New Orleans
,
USA
5 - 8 June 2026
American Diabetes Association (ADA 2026)
Presentation schedule and materials
Friday, 05 June 2026
12:45
- 13:45
CDT
1035-OR
ORAL PRESENTATION
Effects of CagriSema on Appetite and Functional Brain Activity in People with Overweight/Obesity
Nikolaj Bak1; Merita Alex2; Søren A. Fuglsang1; Christa Broholm1; Christian Keicher3; Roni Setton4; Elif Sikoglu5; Eva W. Lehmann1; Janne R. Hingst1
MATERIALS AVAILABLE
18:30
- 20:30
CDT
Symposium
Patient-centric obesity care: from evidence and guidelines to future directions
Donna Ryan
;
Louis J. Aronne
;
Deborah Bade Horn
;
Jaime Almandoz
;
Thomas Lutz
;
Domenica Rubino
MATERIALS AVAILABLE
Saturday, 06 June 2026
06:15
- 07:45
CDT
Symposium
Optimizing T2D Outcomes: A Person-Centred Evolution in Diabetes Care
Alice Cheng
;
Rodica Pop-Busui
;
Marc Bonaca
;
Peter Rossing
;
Athena Philis-Tsimikas
MATERIALS AVAILABLE
12:30
- 13:30
CDT
2350-P
POSTER
Unmet Need in Post-stroke Antidiabetic Treatment Patterns Among Individuals Newly Diagnosed With Type 2 Diabetes (T2D) During Ischemic Stroke Hospitalization
Caichen Zhong1; Lin Xie1; Josh Noone1; Chalak Muhammad1; Sunday Ikpe2; Zhun Cao2; Shanthi Krishnaswami2; Adam de Havenon3
MATERIALS AVAILABLE
12:30
- 13:30
CDT
2838-LB
POSTER
Cardiometabolic effects of semaglutide in OASIS 4 participants by body mass index class
Rubino Domenica1; Wilson Lauren2; Traina Andrea2; Rathor Naveen3; Wang Julia2; Knight Michael4
MATERIALS AVAILABLE
12:30
- 13:30
CDT
1752-P
POSTER
Improved treatment satisfaction with once-weekly IcoSema versus once-daily glargine U100 in insulin-naive adults with T2D (COMBINE 4)
Liming Chen1; Malik Benamar2; Benjamin Hilligsøe Harvey3; Sin Gon Kim4; Laura Pletsch-Borba2; Paolo Fiorina5
MATERIALS AVAILABLE
12:30
- 13:30
CDT
1753-P
POSTER
CGM-based metrics in insulin-naive adults with T2D receiving IcoSema vs glargine U100: post hoc analysis of COMBINE 4
Concetta Irace1; Raluca Maltesen2; Laura Pletsch-Borba3; Thaís M Pagliaro Rocha3; Yasuo Terauchi4; Chantal Mathieu5
MATERIALS AVAILABLE
12:30
- 13:30
CDT
1758-P
POSTER
Efficacy and hypoglycemia outcomes with once-weekly IcoSema vs comparators in T2D by baseline BMI: COMBINE 1-3
Daisuke Yabe1; Raluca Maltesen2; Viswanathan Mohan3; Laura Pletsch-Borba4; Cathrine Scavenius4; Linong Ji5
MATERIALS AVAILABLE
12:30
- 13:30
CDT
1738-P
POSTER
Efficacy and hypoglycemia outcomes with once-weekly IcoSema vs comparators in T2D by baseline A1C: COMBINE 1-3
Viswanathan Mohan1; Raluca Maltesen2; Laura Pletsch-Borba3; Cathrine Scavineus3; Daisuke Yabe4; Linong Ji5
MATERIALS AVAILABLE
12:30
- 13:30
CDT
1750-P
POSTER
Glucodynamics and hypoglycemia risk during exercise or fasting in individuals with type 2 diabetes receiving once-weekly basal insulin icodec
Thomas R Pieber1; Harpreet S Bajaj2; Gabriele Fluhr1; Klara R Klein3; Thaís M Pagliaro Rocha4; Harald Sourij1; Eva Svehlikova1; Keerthana Udupa5; Sara K Watt4; Maria Willerslev-Olsen4; Rasmus Ribel-Madsen4
MATERIALS AVAILABLE
13:30
- 15:00
CDT
2700-LB
POSTER
High-dose subcutaneous semaglutide is associated with preservation of kidney function in people living with obesity without diabetes
Peter Rossing1,2; Christine Sofie Fuchs Jacobsen3; Jøran Hjelmesæth4,5; Kristoffer Jensen Kolnes3; Lauren Wilson6; Katherine Tuttle7,8
MATERIALS AVAILABLE
13:30
- 15:00
CDT
3033-LB
POSTER
Spatiocellular mapping indicates complementary action of amylin and GLP1 receptor agonism in the human brain
Mette Ludwig1; Sarah Bau1; Georgina Dowsett2; Lukas Steuernagel2; Giles Yeo3; Anna Secher1; Kirsten Raun1; Sofia Lundh1
MATERIALS AVAILABLE
Sunday, 07 June 2026
12:30
- 13:30
CDT
1669-P
POSTER
Effect of Semaglutide for Weight Management on Blood Pressure in Adults with Uncontrolled Hypertension and Overweight/Obesity: A Post Hoc Analysis from the STEP and OASIS Programs
Beverly G. Tchang1; Michael G. Knight2; Andrea Traina,3; Lauren Wilson3; Julia Wang3; Jan N. Basile4
MATERIALS AVAILABLE
12:30
- 13:30
CDT
1708-P
POSTER
Comparing Major Adverse Kidney Events (MAKE) Among New Users of Oral Semaglutide (SEMA) Versus Select Oral Antidiabetic Medications (ADMs) Among US Adults With Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)
Lin Xie1; Guanghao Zhang1; Sherif Mehanna1; Josh Noone1; Caroline Swift1; Matthew Weir2,3
MATERIALS AVAILABLE
12:30
- 13:30
CDT
2834-LB
POSTER
Cardiometabolic Outcomes in Adults With Type 2 Diabetes Treated With 1 mg Semaglutide Who Titrate to 2 mg Semaglutide vs Switch to Tirzepatide
Gang Fang1; Chalak Muhammad1; Caroline Swift1; Josh Noone1; Yuanjie Liang1; Kathryn Tierney2
MATERIALS AVAILABLE
12:30
- 13:30
CDT
2717-LB
POSTER
Clinical and Economic Burden Associated With Painful Diabetic Peripheral Neuropathy (PDPN) in Patients With Type 2 Diabetes (T2D)
Yiqiao Zhang1; Lin Xie1; Caroline Swift1; Nathan Laney1; Aaron Asa King2
MATERIALS AVAILABLE
12:30
- 13:30
CDT
2843-LB
POSTER
HbA1c and Weight Outcomes for Individuals With T2D Persistent on Oral Semaglutide 25 mg: A PIONEER PLUS Post Hoc Analysis
Yesha Patel1,2; Josh Noone2; Chethana K. Ramesh3; Chalak Muhammad2
MATERIALS AVAILABLE
12:30
- 13:30
CDT
2836-LB
POSTER
HbA1c and Weight Outcomes Among Adults With Type 2 Diabetes on 25-mg Oral Semaglutide Previously Treated With Metformin Only: A Post Hoc Analysis From PIONEER PLUS
Lin Xie1; Chethana K. Ramesh2; Angelo Navas1,3; Chalak Muhammad1
MATERIALS AVAILABLE
12:30
- 13:30
CDT
2840-LB
POSTER
Semaglutide and Obstructive Sleep Apnea (OSA): A Post Hoc Analysis From SELECT
Silvio E. Inzucchi1; Nina M. Harder-Lauridsen2; Søren Fjelstrup2; Ian J. Neeland3; Andrea Traina4; Lauren Wilson4; Donna H. Ryan5
MATERIALS AVAILABLE
12:30
- 13:30
CDT
2846-LB
POSTER
Efficacy and Safety of Semaglutide by Race and Ethnicity in the SELECT Trial
Jamy Ard1; Michael Knight2; Anders Bo Bojesen3; Domenica Rubino4; Signe Stensen3; Andrea Traina5; Lauren Wilson5; Robert F. Kushner6
MATERIALS AVAILABLE
12:30
- 13:30
CDT
1701-P
POSTER
Longitudinal Dynamics of Cardiometabolic Parameters in a MASH Population Stratified by Baseline Glycemia and Treated with Semaglutide: Post Hoc Insights from the ESSENCE Trial Part 1
Mary E. Rinella1; Maria Teresa Arias-Loste2; Elisabetta Bugianesi3; Laurent Castera4,5;Nathalie M. Eklöf6; Won Kim7; Niels Krarup8; Bernhard Ludvik; Philip N. Newsome9,10; Vlad Ratziu11;Arun J. Sanyal12; Anca Trifan13; Thea C. Vestergaard6;Michael Roden14-16;
MATERIALS AVAILABLE
12:30
- 13:30
CDT
1723-P
POSTER
Semaglutide Reduces Asthma-Related Adverse Outcomes in Patients With Comorbid Asthma and Obesity: A Post Hoc Analysis of the SELECT Trial
Charlotte Suppli Ulrik12; Kjell Erik Julius Håkansson1; Søren Rasmussen3; Miquel Triana Iglesias3; Howraman Meteran14; Robert Kushner5; Kasper Adelborg3; Signe Stensen3; Lotte Bjerre Knudsen6; Sheila Tuyet Tang3
MATERIALS AVAILABLE
12:30
- 13:30
CDT
1703-P
POSTER
Semaglutide Reduces Multi-Organ Proteomic-Based Biological Age Across Cohorts
Maria Dermit1; Alejandro Aguayo-Orozco2; Sarah Amandine Caroline Voisin3; Kasper Adelborg3; Dylan Belmont-Rausch4; Helen Colhoun5; Ludger J.E. Goeminne6; Vadim N. Gladyshev6; Kristoffer Jensen Kolnes3; Donna Ryan7; Lotte Bjerre Knudsen4
MATERIALS AVAILABLE
12:30
- 13:30
CDT
1685-P
POSTER
Exploring semaglutide's effect on the ASCVD-related proteomic signature and their prediction of MACE in SELECT
Maria Dermit1; Alejandro Aguayo-Orozco2; Anne-Mette Bjerregaard3; Fausto Capelluto4; Helen M. Colhoun5; Bjarke Follin3; Kristian Hessellund3; A. Michael Lincoff6; Ildiko Lingvay7; Jorge Plutzky8; Jonas Andreas Sibbesen3; Signe Stensen3; Peter E. Weeke3; Tobias N. Wistisen3; Lotte Bjerre Knudsen4; Steven E. Kahn8
MATERIALS AVAILABLE
12:30
- 13:30
CDT
1696-P
POSTER
Effect of Semaglutide on COVID-19-Related Complications and All-Cause Death: Pooled Analyses of the SELECT, FLOW, and SOUL Trials
Benjamin M. Scirica (MD)1; John B. Buse (MD)2; Andrei-Mircea Catarig (MD)3; Ole Kleist Jeppesen (MSc)3; A. Michael Lincoff (MD)4; Darren K. McGuire (MD, MHSc)5; Vlado Perkovic (MD)6; Richard Pratley (MD)7; Signe Stensen (MD)3; Minh Chau Tran (MSc)3; Donna H. Ryan (MD)8
MATERIALS AVAILABLE
12:30
- 13:30
CDT
2835-LB
POSTER
Greater combined A1C reductions and weight loss with 25 mg and 50 mg versus 14 mg oral semaglutide in adults with T2D: evidence from PIONEER PLUS
Jens Aberle1; Pawel Bogdanski2; Erik Ising3; Chethana KR4; Anusha Jahagirdar4; Sue D. Pedersen5
MATERIALS AVAILABLE
12:30
- 13:30
CDT
LB-5175
POSTER
Glycemic Control Associated with the Use of Dose Check App for Insulin Degludec Titration in People with Type 2 Diabetes: A Prospective, Single-Arm, Real-World Study in Saudi Arabia (DEAL-2)
Mohamed Almehthel1; Khaled Aldossari2; Shahid Akhtar3; Reem Al Argan4; Amal Abu Alsaud5; Faisal Alkhateeb6; Jamal Al Shawaf7; Aref Atta8; Mohamed Daghstani9; Stine Hedegaard Scheuer10; Waleed Shehab11
MATERIALS AVAILABLE
12:30
- 13:30
CDT
2292-P
POSTER
Effect of CagriSema on Eating Control and Behavior: REDEFINE 1
Michelle Dalton1; Matthias Blüher2,3; Christa Baker Broholm4; Christian Bøge Lyndgaard4; Domenica Rubino5; Thomas Wadden6; Torquil Watt4; Kirsi H. Pietiläinen7,8
MATERIALS AVAILABLE
12:30
- 13:30
CDT
2829-LB
POSTER
STEP UP T2D: Participants Achieving BMI, WHtR, and Cardiometabolic Treatment Targets
Carel W. Le Roux1; Sambit Das2; Nina M. Harder-Lauridsen3; Ildiko Lingvay4; Megha Poddar5; Niklas Kahr Rasmussen3; Luca Busetto6
MATERIALS AVAILABLE
13:30
- 14:30
CDT
1730-P
POSTER
Zenagamtide (amycretin), a novel unimolecular GLP-1 and amylin receptor agonist: phase 2 results in T2D
Pablo Mora1; 2; Vanita R Aroda3; Marisse Asong4; Matthias Blüher5; Line Dam Heftdal4; Amanda-Louise Fenger Carlander4; Louise Nygaard Vilsen4; Julio Rosenstock1
MATERIALS AVAILABLE
16:30
- 18:00
CDT
CT-SYXX-1.5
ORAL PRESENTATION
REIMAGINE 1, 2, 3: Leveraging Amylin and GLP-1 for Type 2 Diabetes Care with CagriSema
John B. Buse1; Steven E. Kahn2; Vanita R. Aroda3; Akshay Jain4, 5; Julio Rosenstock6
MATERIALS AVAILABLE
Monday, 08 June 2026
12:30
- 13:30
CDT
2592-P
POSTER
Impact of Once-Weekly Injectable Semaglutide Versus Placebo on Fatty Liver Index Scores in People with Overweight/Obesity: A Post Hoc Analysis (STEP 1)
Gema Frühbeck1; Maximilian Jara2; Naveen Rathor3; Jonathan Sudkamp4; Lauren Wilson2
MATERIALS AVAILABLE
14:00
- 14:15
CDT
1291-OR
ORAL PRESENTATION
Serum Proteomics Suggest Novel Mechanisms of Action of Semaglutide in Reducing the Risk of MACE in the SELECT Trial
Helen M. Colhoun1; John E. Deanfield2; Steven E. Kahn3; A. Michael Lincoff4; Ildiko Lingvay5; Jorge Plutzky6; Kristian Hessellund7; G. Kees Hovingh7; Kristoffer Jensen Kolnes7; Peter E. Weeke7; Lotte Bjerre Knudsen8; Jan Christian Refsgaard7
MATERIALS AVAILABLE
14:30
- 14:45
CDT
1311-OR
ORAL PRESENTATION
Achieving at least 15% weight loss within 2 years of T2D diagnosis is associated with a lower long-term risk of micro- and macrovascular disease: A UK cohort study
Naveed Sattar1; Jessica Bengtsson2; Tariq Halasa2; Amine Lotfi2; Claire P. Miller2; Eva Johnsen2
MATERIALS AVAILABLE
Keywords